Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Novartis Announced Kisqali Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those with Aggressive HR+/HER2- Advanced Breast Cancer

By Charles Gross
Today, 3:10 AM
Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.

NVS

Read More
2 minute read

Novartis Scemblix Approved by the European Commission for Adult Patients with Chronic Myeloid Leukemia

By Charles Gross
Today, 3:10 AM
Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)1.Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for th

NVS